Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Arcturus Therapeutics Holdings Inc (ARCT) operate in?
Arcturus Therapeutics Holdings Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Arcturus Therapeutics Holdings Inc (ARCT) current stock price?
As of the latest data, Arcturus Therapeutics Holdings Inc stock price is $8.23, with a previous close of $7.86. Arcturus Therapeutics Holdings Inc gained $0.37 in the last trading session, representing a 4.71% increase.
What is Arcturus Therapeutics Holdings Inc (ARCT) current market capitalization?
Arcturus Therapeutics Holdings Inc market cap is approximately 233.92 million.
What is Arcturus Therapeutics Holdings Inc (ARCT) Earnings Per Share (EPS)?
The trailing EPS is -$3.33, and the forward EPS is -$4.01.
What is Arcturus Therapeutics Holdings Inc (ARCT) EBITDA?
Arcturus Therapeutics Holdings Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -23.79 million.
Does Arcturus Therapeutics Holdings Inc (ARCT) pay dividends?
No. Arcturus Therapeutics Holdings Inc does not pay a dividend.
How did Arcturus Therapeutics Holdings Inc (ARCT) perform in its most recent earnings report?
In the last report (June 30, 2026), Arcturus Therapeutics Holdings Inc posted an EPS surprise of 21.5% and a revenue surprise of -5.25%.
What is Arcturus Therapeutics Holdings Inc (ARCT) beta (volatility) score?
Arcturus Therapeutics Holdings Inc has a beta of 2.271, indicating very high volatility compared to the market.
Unfortunately, you do not have access to this data. Make sure you have an active subscription.
